Fig. 8 The presence of macrophages in brain parenchyma adjacent to the former tumor bed 
is indicated by immunocytochemical localization of EDI antigen on cells (representatives 
shown by arrowheads). 
Fig. 9 The effect of GCV dose on brain tumor 
size after adenovirus-mediated gene therapy. 
Small residual tumors were noted in some 
brains of ADV/tk treated rats that received 
less than 80 mg/kg GCV. Error bars = S.D. 
Treatments, mean tumor areas ± S.D., 
and sample sizes are: A ADV-tk + PBS, 
36.89±6.73 mm 2 (n=3); B ADV-bgal + 150 
mg/kg GCV, 28.75±0.55 mm 2 (n=4); C ADV- 
tk + 150 mg/kg GCV, 0 mm 2 (n=2); D ADV-tk 
+ 100 mg/kg GCV. 0 mm 2 (n=4); E ADV-tk + 
80 mg/kg GCV, 0 mm 2 (n=2J; F ADV-tk + 50 
mg/kg GCV. 0.25±0.29 mm (n=4); G ADV-tk 
+ 20 mg/kg GCV, 0.029±0.01 mm 2 (n=3)*; H 
ADV-tk + 10 mg/kg GCV, 0.01 ±0.004 mm 2 
(n=4). (Note: One animal was removed from 
group G that had a large (7.06 mm 2 ) tumor.) 
Maximal Tumor Area (mm?) 
0 10 20 30 40 50 
Recombinant DNA Research, Volume 20 
